Spero Therapeutics (SPRO) Operating Margin (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Operating Margin came in at 232.46% in Q4 2025, up 4201131.0% YoY from N/an in Q4 2024, and up 100.19% on a QoQ basis from 122758.33% in Q1 2025.
Spero Therapeutics (SPRO) Operating Margin (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 10 years of Operating Margin data on file, last reported at 232.46% in Q4 2025.
- Quarterly Operating Margin rose 4201131.0% year-over-year to 232.46% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 94.52% (up 80103.0% YoY) and the FY2025 annual result came in at 50.11%, up 1982397.0% from the prior year.
- Operating Margin improved to 232.46% in Q4 2025, from 122758.33% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 232.46% in Q4 2025 to a low of 122758.33% in Q1 2025.
- A 5-year average of 12667.8% and a median of 784.16% in 2022 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2021 — Operating Margin soared 4687128 bps — and 2025, when it sank 11277119 bps.
- Tracing SPRO's Operating Margin over 5 years: stood at 221.04% in 2021, then tumbled by 41 bps to 129.39% in 2022, then sank by 226 bps to 162.5% in 2023, then slumped by 25610 bps to 41778.85% in 2024, then surged by 101 bps to 232.46% in 2025.
- The last three Operating Margin figures came in at 232.46% (Q4 2025), 122758.33% (Q1 2025), and 41778.85% (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,921.71% |
| Dec 31, 2025 | 232.46% |
| Mar 31, 2025 | -122,758.33% |
| Dec 31, 2024 | -41,778.85% |
| Sep 30, 2024 | -26,826.15% |
| Jun 30, 2024 | -186.93% |
| Mar 31, 2024 | -9,987.14% |
| Dec 31, 2023 | -162.50% |
| Sep 30, 2023 | -7.59% |
| Jun 30, 2023 | -474.59% |
| Mar 31, 2023 | -6,379.82% |
| Dec 31, 2022 | 129.39% |
| Sep 30, 2022 | -1,093.72% |
| Jun 30, 2022 | -2,910.71% |
| Mar 31, 2022 | -12,229.55% |
| Dec 31, 2021 | 221.04% |
| Sep 30, 2021 | -3,181.36% |
| Jun 30, 2021 | -360.18% |
| Mar 31, 2021 | -265.79% |
| Sep 30, 2020 | -50,052.63% |